Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036341 (
schizophrenia
)
60,220
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
High levels of D-serine are found in mammalian brain, where it is an endogenous agonist of the strichinine-insensitive site of N-methyl D-aspartate type of glutamate receptors. D-serine is enriched in protoplasmic astrocytes that occur in gray matter areas of the brain and was shown to be synthesized from L-serine. We now report cloning and expression of human
serine racemase
, an enzyme that catalyses the synthesis of D-serine from L-serine. The enzyme displays a high homology to the murine
serine racemase
. It contains a pyridoxal 5'-phosphate attachment sequence similar to bacterial biosynthetic threonine dehydratase. Northern-blot analysis show high levels of human
serine racemase
in areas known to contain large amounts of endogenous D-serine, such as hippocampus and corpus callosum. Robust synthesis of D-serine was detected in cells transfected with human
serine racemase
, demonstrating the conservation of D-amino acid metabolism in humans. Serine racemase may be a therapeutic target in psychiatric diseases as supplementation of D-serine greatly improves
schizophrenia
symptoms. We identify the human
serine racemase
genomic structure and show that the gene encompasses seven exons and localizes to chromosome 17q13.3. Identification of the intron-exon boundaries of the human
serine racemase
gene will be useful to search for mutations in neuropsychiatric disorders.
...
PMID:Human serine racemase: moleular cloning, genomic organization and functional analysis. 1105 47
The N-methyl D-aspartate (NMDA) type of glutamate receptor requires two distinct agonists to operate. Glycine is assumed to be the endogenous ligand for the NMDA receptor glycine site, but this notion has been challenged by the discovery of high levels of endogenous d-serine in the mammalian forebrain. I have outlined an evolutionary framework for the appearance of a glycine site in animals and the metabolic events leading to high levels of D-serine in brain. Sequence alignments of the glycine-binding regions, along with the scant experimental data available, suggest that the properties of invertebrate NMDA receptor glycine sites are probably different from those in vertebrates. The synthesis of D-serine in brain is due to a pyridoxal-5'-phosphate (B(6))-requiring
serine racemase
in glia. Although it remains unknown when
serine racemase
first evolved, data concerning the evolution of B(6) enzymes, along with the known occurrences of serine racemases in animals, point to D-serine synthesis arising around the divergence time of arthropods. D-Serine catabolism occurs via the ancient peroxisomal enzyme d-amino acid oxidase (DAO), whose ontogenetic expression in the hindbrain of mammals is delayed until the postnatal period and absent from the forebrain. The phylogeny of D-serine metabolism has relevance to our understanding of brain ontogeny,
schizophrenia
and neurotransmitter dynamics.
...
PMID:The N-methyl D-aspartate receptor glycine site and D-serine metabolism: an evolutionary perspective. 1530 9
Accumulating evidence from both genetic and clinico-pharmacological studies suggests that D-serine, an endogenous coagonist to the NMDA subtype glutamate receptor, may be implicated in
schizophrenia
(SZ). Although an association of genes for D-serine degradation, such as D-amino acid oxidase and G72, has been reported, a role for D-serine in SZ has been unclear. In this study, we identify and characterize protein interacting with C-kinase (PICK1) as a protein interactor of the D-serine synthesizing enzyme,
serine racemase
(SR). The binding of endogenous PICK1 and SR requires the PDZ domain of PICK1. The gene coding for PICK1 is located at chromosome 22q13, a region frequently linked to SZ. In a case-control association study using well-characterized Japanese subjects, we observe an association of the PICK1 gene with SZ, which is more prominent in disorganized SZ. Our findings implicating PICK1 as a susceptibility gene for SZ are consistent with a role for D-serine in the disease.
...
PMID:Serine racemase binds to PICK1: potential relevance to schizophrenia. 1631 70
Evidence of glutamatergic dysfunction in
schizophrenia
associated with the N-methyl-D-aspartate receptor has historically demonstrated changes primarily attributable to neurons. We propose an astrocytic component to N-methyl-D-aspartate receptor dysfunction in this illness. We studied the expression of
serine racemase
, an astrocytic enzyme which synthesizes the N-methyl-D-aspartate receptor coagonist D-serine, using Western blot analysis in postmortem hippocampus and cortex in
schizophrenia
and a comparison group. We found increased expression in the hippocampus in
schizophrenia
. This is the first study to demonstrate alterations in
schizophrenia
of an astrocytic enzyme responsible for synthesizing a neuromodulator, and further evidence that astrocytes may play a direct role in N-methyl-D-aspartate receptor dysfunction in
schizophrenia
.
...
PMID:Serine racemase protein expression in cortex and hippocampus in schizophrenia. 1683 50
Clinical trials demonstrated that D-serine administration improves
schizophrenia
symptoms, raising the possibility that altered levels of endogenous D-serine may contribute to the N-methyl D-aspartate receptor hypofunction thought to play a role in the disease. We hypothesized that cerebro-spinal fluid (CSF) D-serine levels are decreased in the patients due to reduced synthesis and/or increased degradation in brain. We now monitored amino acid levels in CSF from 12
schizophrenia
patients vs. 12 controls and in postmortem parietal-cortex from 15 control subjects and 15 each of
schizophrenia
, major-depression and bipolar patients. In addition, we monitored postmortem brain
serine racemase
and D-amino acid oxidase protein levels by Western-blot analysis. We found a 25% decrease in D-serine levels and D/L-serine ratio in CSF of
schizophrenia
patients, while parietal-cortex D-serine was unaltered. Levels of L-serine, L-glutamine and L-glutamate were unaffected. Frontal-cortex (39%) and hippocampal (21%)
serine racemase
protein levels and hippocampal
serine racemase
/D-amino acid oxidase ratio (34%) were reduced. Hippocampal D-amino-acid-oxidase protein levels significantly correlated with duration of illness (r=0.6, p=0.019) but not age. D-amino acid oxidase levels in patients with DOI>20 years were 77% significantly higher than in the other patients and controls. Our results suggest that reduced brain
serine racemase
and elevated D-amino acid oxidase protein levels may contribute to the lower CSF D-serine levels in
schizophrenia
.
...
PMID:A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. 1715 77
D-Serine has recently been identified as a major gliotransmitter in the mammal central nervous system (CNS). The distribution of D-serine is analogous to the N-methyl-D-aspartate (NMDA)-type glutamate receptors in the brain. D-Serine is as potent as glycine as a coagonist at the glycine-binding site of NMDA receptors. Thus, D-serine has been considered as an endogenous ligand of the NMDA receptors in the brain. D-Serine is synthesized by
serine racemase
(SR) from L-serine. Both D-serine and SR have been enriched to astrocytes which are the dynamic partners of neurons at synapses and participate in controlling synaptic transmission, synaptic plasticity and synaptogenesis. The present review highlights the most recent findings on the molecular mechanisms of controlling D-serine metabolism in the CNS, the physiological role of D-serine in synaptic plasticity, and the pathological relevance of D-serine to
schizophrenia
, excitotoxicity- and neuroinflammation-induced neuronal death as well as neuropathic pain. Finally, as we have recently established SR knockout mouse strain with pure C57BL/6 genetic background, this novel mouse model will contribute the analysis of physiological and pathophysiological role of D-serine in vivo.
...
PMID:[Role of D-serine in the mammalian brain]. 1766 43
The N-methyl-D-aspartate receptor co-agonist d-serine is synthesized by
serine racemase
and degraded by D-amino acid oxidase. Both D-serine and its metabolizing enzymes are implicated in N-methyl-D-aspartate receptor hypofunction thought to occur in
schizophrenia
. We studied D-amino acid oxidase and
serine racemase
immunohistochemically in several brain regions and compared their immunoreactivity and their mRNA levels in the cerebellum and dorsolateral prefrontal cortex in
schizophrenia
. D-Amino acid oxidase immunoreactivity was abundant in glia, especially Bergmann glia, of the cerebellum, whereas in prefrontal cortex, hippocampus and substantia nigra, it was predominantly neuronal. Serine racemase was principally glial in all regions examined and demonstrated prominent white matter staining. In
schizophrenia
, D-amino acid oxidase mRNA was increased in the cerebellum, and as a trend for protein. Serine racemase was increased in
schizophrenia
in the dorsolateral prefrontal cortex but not in cerebellum, while
serine racemase
mRNA was unchanged in both regions. Administration of haloperidol to rats did not significantly affect
serine racemase
or D-amino acid oxidase levels. These findings establish the major cell types wherein
serine racemase
and D-amino acid oxidase are expressed in human brain and provide some support for aberrant D-serine metabolism in
schizophrenia
. However, they raise further questions as to the roles of D-amino acid oxidase and
serine racemase
in both physiological and pathophysiological processes in the brain.
...
PMID:d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. 1788 Mar 99
D-serine serves as a co-agonist of the N-methyl D-aspartate receptor in mammalian brains, and its behavior is probably related to neurological disorders such as
schizophrenia
, Alzheimer's disease and amyotrophic lateral sclerosis. D-Serine is synthesized by a pyridoxal 5'-phosphate (PLP)-dependent
serine racemase
. In this minireview, we provide a detailed discussion on the reaction mechanism of the PLP-dependent amino acid racemase on the basis of its 3D structure. We compared the eukaryotic
serine racemase
with bacterial alanine racemase, the best-studied enzyme among the PLP-dependent amino acid racemases, and thus suggested a putative reaction mechanism for mammalian D-serine synthesis.
...
PMID:D-amino acids in the brain: structure and function of pyridoxal phosphate-dependent amino acid racemases. 1856 79
Abnormal N-methyl-d-aspartate receptor (NMDAR) function has been implicated in the pathophysiology of
schizophrenia
. d-serine is an important NMDAR modulator, and to elucidate the role of the d-serine synthesis enzyme
serine racemase
(Srr) in
schizophrenia
, we identified and characterized mice with an ENU-induced mutation that results in a complete loss of Srr activity and dramatically reduced d-serine levels. Mutant mice displayed behaviors relevant to
schizophrenia
, including impairments in prepulse inhibition, sociability and spatial discrimination. Behavioral deficits were exacerbated by an NMDAR antagonist and ameliorated by d-serine or the atypical antipsychotic clozapine. Expression profiling revealed that the Srr mutation influenced several genes that have been linked to
schizophrenia
and cognitive ability. Transcript levels altered by the Srr mutation were also normalized by d-serine or clozapine treatment. Furthermore, analysis of SRR genetic variants in humans identified a robust association with
schizophrenia
. This study demonstrates that aberrant Srr function and diminished d-serine may contribute to
schizophrenia
pathogenesis.
...
PMID:Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. 1948 94
D-serine is an endogenous N-methyl-D-aspartate (NMDA) receptor coagonist. It is synthesized from L-serine by
serine racemase
(
SRR
), but many aspects of its metabolism remain unclear, especially in the forebrain, which lacks active D-amino acid oxidase (DAO), the major D-serine degradative enzyme. Candidate mechanisms include
SRR
operating in alpha,beta-eliminase mode (converting D-serine to pyruvate) and regulation by serine transport, in which the alanine-serine-cysteine transporter ASCT2 is implicated. Here we report studies in C6 glioma cells, which "simulate" the forebrain, in that the cells express
SRR
and ASCT2 but lack DAO activity. We measured D-serine, ASCT2,
SRR
, and DAO expression and DAO activity in two situations: after incubation of cells for 48 hr with serine isomers and after increased or decreased
SRR
expression by transfection and RNA interference, respectively. Incubation with serine enantiomers decreased [(3)H]D-serine uptake and ASCT2 mRNA and increased
SRR
immunoreactivity but did not alter DAO immunoreactivity, and DAO activity remained undetectable.
SRR
overexpression increased D-serine and pyruvate and decreased [(3)H]D-serine uptake and ASCT2 mRNA but did not affect DAO.
SRR
knockdown did not alter any of the parameters. Our data suggest that D-serine transport mediated by ASCT2 contributes prominently to D-serine homeostasis when DAO activity is absent. The factors regulating D-serine are important for understanding normal NMDA receptor function and because D-serine, along with DAO and
SRR
, is implicated in the pathogenesis and treatment of
schizophrenia
.
...
PMID:D-Serine metabolism in C6 glioma cells: Involvement of alanine-serine-cysteine transporter (ASCT2) and serine racemase (SRR) but not D-amino acid oxidase (DAO). 2009 74
1
2
3
4
5
Next >>